Presence of Anti-Microbial Antibodies in Liver Cirrhosis – A Tell-Tale Sign of Compromised Immunity?

Background Bacterial translocation plays important role in the complications of liver cirrhosis. Antibody formation against various microbial antigens is common in Crohn's disease and considered to be caused by sustained exposure to gut microflora constituents. We hypothesized that anti-microbial antibodies are present in patients with liver cirrhosis and may be associated with the development of bacterial infections. Methodology/Principal Findings Sera of 676 patients with various chronic liver diseases (autoimmune diseases:266, viral hepatitis C:124, and liver cirrhosis of different etiology:286) and 100 controls were assayed for antibodies to Saccharomyces cerevisiae(ASCA) and to antigens derived from two intestinal bacterial isolates (one gram positive, one gram negative, neither is Escherichia coli). In patients with liver cirrhosis, we also prospectively recorded the development of severe episodes of bacterial infection. ASCA and anti-OMP Plus™ antibodies were present in 38.5% and 62.6% of patients with cirrhosis and in 16% and 20% of controls, respectively (p<0.001). Occurrence of these antibodies was more frequent in cases of advanced cirrhosis (according to Child-Pugh and MELD score; p<0.001) or in the presence of ascites (p<0.001). During the median follow-up of 425 days, 81 patients (28.3%) presented with severe bacterial infections. Anti-microbial antibody titers (p = 0.003), as well as multiple seroreactivity (p = 0.036), was associated with infectious events. In logistic regression analysis, the presence of ascites (OR:1.62, 95%CI:1.16–2.25), co-morbidities (OR:2.22, 95%CI:1.27–3.86), and ASCA positivity (OR:1.59, 95%CI:1.07–2.36) were independent risk factors for severe infections. A shorter time period until the first infection was associated with the presence of ASCA (p = 0.03) and multiple seropositivity (p = 0.037) by Kaplan-Meier analysis, and with Child-Pugh stage (p = 0.018, OR:1.85) and co-morbidities (p<0.001, OR:2.02) by Cox-regression analysis. Conclusions/Significance The present study suggests that systemic reactivity to microbial components reflects compromised mucosal immunity in patients with liver cirrhosis, further supporting the possible role of bacterial translocation in the formation of anti-microbial antibodies.

[1]  T. Barrientos-Gutiérrez,et al.  Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. , 2010, The Cochrane database of systematic reviews.

[2]  M. Papp,et al.  Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis. , 2010, Journal of hepatology.

[3]  F. Lammert,et al.  Nucleotide‐binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis , 2010, Hepatology.

[4]  F. Klebl,et al.  Association of the novel serologic anti‐glycan antibodies anti‐laminarin and anti‐chitin with complicated Crohn's disease behavior , 2010, Inflammatory bowel diseases.

[5]  G. Veres,et al.  Anti-microbial antibodies in celiac disease: trick or treat? , 2009, World journal of gastroenterology.

[6]  J. C. Hernandez,et al.  Oral Antibiotic Prophylaxis Reduces Spontaneous Bacterial Peritonitis Occurrence and Improves Short-Term Survival in Cirrhosis: A Meta-Analysis , 2009, The American Journal of Gastroenterology.

[7]  J. González-Navajas,et al.  Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis , 2008, Hepatology.

[8]  M. Pirlich,et al.  Gastrointestinal tract in liver disease: which organ is sick? , 2008, Current opinion in clinical nutrition and metabolic care.

[9]  M. Mikuła,et al.  Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients , 2008, BMC Medical Genetics.

[10]  K. Prasad,et al.  Functional and morphological alterations in small intestine mucosa of chronic alcoholics , 2008, Journal of gastroenterology and hepatology.

[11]  W. Sakly,et al.  Anti-Saccharomyces cerevisiae Antibodies in Primary Biliary Cirrhosis , 2008, Digestive Diseases and Sciences.

[12]  P. Rutgeerts,et al.  (Auto)antibodies in inflammatory bowel diseases. , 2008, Gastroenterology clinics of North America.

[13]  P. Hill,et al.  Coeliac disease: a biopsy is not always necessary for diagnosis , 2008, Alimentary pharmacology & therapeutics.

[14]  T. Molnár,et al.  New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.

[15]  P. Tandon,et al.  Bacterial infections, sepsis, and multiorgan failure in cirrhosis. , 2008, Seminars in liver disease.

[16]  G. Jung,et al.  Model for end-stage liver disease , 2008, Der Chirurg.

[17]  M. Navasa,et al.  Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. , 2007, Gastroenterology.

[18]  G. Veres,et al.  Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients , 2007, Inflammatory bowel diseases.

[19]  P. Rutgeerts,et al.  Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease , 2007, Gut.

[20]  M. Papp,et al.  Utility of serological markers in inflammatory bowel diseases: gadget or magic? , 2007, World journal of gastroenterology.

[21]  B. Zilberstein,et al.  Bacterial translocation: Overview of mechanisms and clinical impact , 2007, Journal of gastroenterology and hepatology.

[22]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[23]  A. Mankaï,et al.  Anti-Saccharomyces cerevisiae antibodies in coeliac disease , 2007, Scandinavian journal of gastroenterology.

[24]  A. Gressner,et al.  [Elevated concentrations of fecal calprotectin in patients with liver cirrhosis]. , 2006, Deutsche medizinische Wochenschrift.

[25]  S. Targan,et al.  Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. , 2006, Gastroenterology.

[26]  W. Stremmel,et al.  The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis , 2006, European journal of gastroenterology & hepatology.

[27]  G. D. De Palma,et al.  Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. , 2005, Gastrointestinal endoscopy.

[28]  D. Valla,et al.  Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. , 2005, Journal of hepatology.

[29]  A. Burroughs,et al.  Infection, coagulation, and variceal bleeding in cirrhosis , 2005, Gut.

[30]  R. Wiest,et al.  Bacterial translocation (BT) in cirrhosis , 2005, Hepatology.

[31]  G. Soriano,et al.  Bacterial translocation and its consequences in patients with cirrhosis , 2005, European journal of gastroenterology & hepatology.

[32]  P. Lakatos,et al.  NOD2/CARD15 SNP8, 12 and 13 and other EXON4 mutations and primary biliary cirrhosis (PBC) in Hungarian and Polish patients , 2004 .

[33]  M. Álvarez-Mon,et al.  Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites , 2004, The Lancet.

[34]  R. Wiest,et al.  Gut microflora in the pathogenesis of the complications of cirrhosis. , 2004, Best practice & research. Clinical gastroenterology.

[35]  M. Álvarez-Mon,et al.  Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. , 2004, Journal of hepatology.

[36]  W. Mow,et al.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. , 2004, Gastroenterology.

[37]  M. Wagener,et al.  Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  E. Björnsson,et al.  Small Intestinal Motility Disturbances and Bacterial Overgrowth in Patients With Liver Cirrhosis and Portal Hypertension , 2003, American Journal of Gastroenterology.

[39]  J. Calleja,et al.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement , 2003, Hepatology.

[40]  J. Aponte,et al.  Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis , 2001, American Journal of Gastroenterology.

[41]  P. Angeli,et al.  Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[42]  遠藤 昌夫.  Bacterial Translocation (BT) , 2000 .

[43]  M. Manns,et al.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.

[44]  I. Hirata,et al.  Increased prevalence of intestinal inflammation in patients with liver cirrhosis. , 1999, World journal of gastroenterology.

[45]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[46]  A. West,et al.  Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. , 1995, Gastroenterology.

[47]  T. Ueno,et al.  Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. , 1993, The American journal of gastroenterology.

[48]  M. Manns,et al.  The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. , 2008, Journal of hepatology.

[49]  A. Granito,et al.  Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. , 2006, Gut.

[50]  P. Gionchetti,et al.  Anti‐Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases , 2003, Clinical and experimental immunology.

[51]  L. Leibovici,et al.  Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. , 2002, The Cochrane database of systematic reviews.

[52]  L. Grande,et al.  Bacterial translocation of enteric organisms in patients with cirrhosis. , 2001, Journal of hepatology.

[53]  K. Reddy,et al.  Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. , 2001, The American journal of gastroenterology.

[54]  K. Lindor,et al.  Primary biliary cirrhosis , 1998, Springer Netherlands.

[55]  M. J. López Arias,et al.  Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. , 1996, Digestive diseases and sciences.

[56]  E. Strauss,et al.  A prospective study of bacterial infections in patients with cirrhosis. , 1993, Journal of hepatology.